Publications by authors named "H Herrscher"
Progress in Immune Checkpoint Inhibitor for Melanoma Therapy.
Hematol Oncol Clin North Am
October 2024
Melanoma has seen the most remarkable therapeutic improvements among all cancers in the past decade, primarily due to the development of immune checkpoint inhibitors (ICI). Initially developed in the patients with advanced disease, ICI are now used in adjuvant and neoadjuvant settings. More recently, the development of LAG-3 blocking antibody and the combination of ICI with a personalized RNA-based vaccine have continued to lead the immunotherapeutic field.
View Article and Find Full Text PDFMistletoe, Viscum album, is a medicinal plant used in complementary medicine in oncology. Patients do not necessarily mention to their oncologist this phytotherapeutic treatment which may be responsible for unsuspected drug interactions. Some patients are adept at taking medicinal plants, a practice often unknown to health professionals who take care of them.
View Article and Find Full Text PDFImmune checkpoint inhibitors for treatment of advanced stage melanoma. Immunotherapy, which stimulates the anti-tumor immune response, has significantly modified the prognosis of advanced stage melanoma. Anti-CTLA4 monoclonal antibody, ipilimumab, showed a benefit on survival compared to chemotherapy in 2011.
View Article and Find Full Text PDFArticle Synopsis
- * While long-term treatment-free remissions have been noted in other cancers, there is still no clear consensus on the optimal duration of ICI treatment, highlighting the need for more randomized controlled trials.
- * The text suggests that, particularly for melanoma patients, it is generally considered safe to stop ICI therapy after confirming a CR and having at least 6 months of treatment, and it discusses the implications of this treatment cessation for patient management.